SCHEMBL1004065

SCHEMBL1004065

CN(C)C(=O)c1ccc(C(N)=O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.59
HPGD P15428 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
PARP10 Q53GL7 5/20 0.50
PARP4 Q9UKK3 2/20 0.50
PARP1 P09874 2/20 0.50
CA2 P00918 2/20 0.50
CA1 P00915 1/20 0.50
PARP2 Q9UGN5 1/20 0.50
KMT2A Q03164 1/20 0.48
PARP15 Q460N3 1/20 0.48
PARP14 Q460N5 1/20 0.48
PARP16 Q8N5Y8 1/20 0.48
PARP11 Q9NR21 1/20 0.48
MAPT P10636 2/20 0.48
TSHR P16473 2/20 0.48
POLB P06746 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C19 P33261 1/20 0.48
RECQL P46063 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22259605 0.94 LRRK2 (0.55) ALDH1A1HPGDSMN1; SMN2PARP10PARP4
SCHEMBL1004649 0.87 ALDH1A1 (0.73) ALDH1A1HPGDSMN1; SMN2KMT2AMAPT
Nonane SCHEMBL28429388 0.87 MEN1 (0.54) ALDH1A1HPGDSMN1; SMN2PARP10KMT2A
Terephthalamide SCHEMBL27683041 0.85 PARP10 (0.58) ALDH1A1PARP10PARP4PARP1CA2
SCHEMBL8881536 0.81 LCK (0.58) ALDH1A1HPGDSMN1; SMN2PARP10PARP4
SCHEMBL354426 0.81 ALDH1A1 (0.59) ALDH1A1HPGDSMN1; SMN2PARP10KMT2A
SCHEMBL10626283 0.80 ALDH1A1 (0.64) ALDH1A1HPGDSMN1; SMN2KMT2AMAPT
Terephthalamide SCHEMBL23774 0.79 PARP1 (0.71) ALDH1A1SMN1; SMN2PARP10PARP4PARP1
SCHEMBL128134 0.79 PARP1 (0.57) PARP10PARP1PARP2KMT2APARP15
SCHEMBL29562303 0.79 PARP1 (0.57) PARP10PARP1PARP2KMT2APARP15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651988-A1 METHODS OF MAKING METAL-ORGANIC FRAMEWORKS WITH PRE-LIGANDS ExxonMobil Technology and Engineering Company (US) 2025-11-26 EP claimed
US-12344623-B2 Thiazolopyridine derivatives as adenosine receptor antagonists DOMAIN THERAPEUTICS SA (FR) 2025-07-01 US claimed
CN-118931094-A GTRB polymer composite sole material and manufacturing method of customized sole 东莞市永铠运动用品有限公司 2024-11-12 CN claimed
WO-2024155562-A1 METHODS OF MAKING METAL-ORGANIC FRAMEWORKS WITH PRE-LIGANDS ExxonMobil Technology and Engineering Company (US) 2024-07-25 WO claimed
CN-118240323-A Antibacterial fiber sponge material and preparation method thereof 扬州中天海绵有限公司 2024-06-25 CN claimed
CN-118240387-A Mildew-proof sponge material and preparation method thereof 扬州中天海绵有限公司 2024-06-25 CN claimed
CN-116442618-A Decorative board and manufacturing method thereof 财纳福诺木业(中国)有限公司 2023-07-18 CN claimed
CN-112574567-B High-strength organic silicon foam plastic and preparation method thereof 漳州普瑞邦节能科技有限公司 2022-11-22 CN claimed
US-20220306588-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-09-29 US claimed
US-11453647-B2 Benzimidazole derivatives as adenosine receptor antagonists MERCK PATENT GMBH (DE) 2022-09-27 US claimed
US-8222248-B2 Organic compounds NOVARTIS AG (CH) 2012-07-17 US claimed
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-07-29 US claimed
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 US claimed
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides DING QINGJIE 2010-03-25 US claimed
EP-2074089-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2009-07-01 EP claimed
WO-2008048991-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-04-24 WO claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
US-20060276496-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-12-07 US claimed
EP-0138265-B1 PROCESS FOR THE PRODUCTION OF EXPANDED RETICULATED POLYETHYLENE AGIP PETROLI S.p.A. (IT) 1989-04-05 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344623-B2 Thiazolopyridine derivatives as adenosine receptor antagonists ADORA1, ADORA2A, ADORA3 ALDH1A1 233/4885HPGD 596/4885SMN1; SMN2 4508/4885
US-20220306588-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS ADORA1, ADORA2A, ADORA3 ALDH1A1 1065/4885HPGD 2089/4885SMN1; SMN2 4438/4885
US-20060276496-A1 Anti-Cytokine Heterocyclic Compounds MAPKAPK2, MAP4K2, MAP3K2 ALDH1A1 3894/4885HPGD 635/4885SMN1; SMN2 3033/4885
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 ALDH1A1 2027/4885HPGD 2440/4885SMN1; SMN2 2109/4885
US-11453647-B2 Benzimidazole derivatives as adenosine receptor antagonists ADORA1, ADORA2A, ADORA3 ALDH1A1 617/4885HPGD 1187/4885SMN1; SMN2 4217/4885
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds MAPKAPK2, MAP4K2, MAP3K2 ALDH1A1 3894/4885HPGD 635/4885SMN1; SMN2 3033/4885
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL ALDH1A1 1278/4885HPGD 3765/4885SMN1; SMN2 4705/4885
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 ALDH1A1 2027/4885HPGD 2440/4885SMN1; SMN2 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.